The Investor
30 Sep 2026, 18:55
Kenvue Highlights New Neutrogena, Aveeno and Regaine Research at EADV 2026
Kenvue announced that its Neutrogena, Aveeno and Regaine brands will present 12 new scientific data sets at the 2026 European Academy of Dermatology and Venereology Congress, covering skin barrier health, acne, hyperpigmentation, eczema, UV-related damage and hair loss.
Neutrogena research highlighted multifunctional sunscreens containing ingredients such as niacinamide and trehalose. One study reported reductions in visible redness, acne-related hyperpigmentation, skin oiliness and shine, while another showed improved hydration, skin tone uniformity and reductions in visible facial spots.
Aveeno studies focused on colloidal oat formulations. Research found support for skin barrier proteins, hydration and ceramide production following UV exposure. A separate international clinician survey also highlighted the use of colloidal oat-based emollients alongside topical corticosteroids in eczema care.
Regaine research examined 5% minoxidil in male androgenetic alopecia. A post-hoc analysis found greater hair regrowth among younger men and patients at earlier stages of hair loss, while improvements versus placebo were observed across all hair-loss classifications studied.
The findings support Kenvue’s broader effort to strengthen its consumer health portfolio with clinically backed research across skin and hair care.
Kenvue announced that its Neutrogena, Aveeno and Regaine brands will present 12 new scientific data sets at the 2026 European Academy of Dermatology and Venereology Congress, covering skin barrier health, acne, hyperpigmentation, eczema, UV-related damage and hair loss.
Neutrogena research highlighted multifunctional sunscreens containing ingredients such as niacinamide and trehalose. One study reported reductions in visible redness, acne-related hyperpigmentation, skin oiliness and shine, while another showed improved hydration, skin tone uniformity and reductions in visible facial spots.
Aveeno studies focused on colloidal oat formulations. Research found support for skin barrier proteins, hydration and ceramide production following UV exposure. A separate international clinician survey also highlighted the use of colloidal oat-based emollients alongside topical corticosteroids in eczema care.
Regaine research examined 5% minoxidil in male androgenetic alopecia. A post-hoc analysis found greater hair regrowth among younger men and patients at earlier stages of hair loss, while improvements versus placebo were observed across all hair-loss classifications studied.
The findings support Kenvue’s broader effort to strengthen its consumer health portfolio with clinically backed research across skin and hair care.
